Olstein Capital Management L.P. increased its stake in Charles River Laboratories International Inc. (NYSE:CRL) by 53.2% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 85,625 shares of the company’s stock after buying an additional 29,724 shares during the period. Olstein Capital Management L.P. owned approximately 0.18% of Charles River Laboratories International worth $7,136,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. raised its position in shares of Charles River Laboratories International by 3.6% in the second quarter. Vanguard Group Inc. now owns 4,513,769 shares of the company’s stock valued at $372,114,000 after buying an additional 157,711 shares in the last quarter. FMR LLC raised its position in shares of Charles River Laboratories International by 19.5% in the second quarter. FMR LLC now owns 2,158,477 shares of the company’s stock valued at $177,945,000 after buying an additional 351,630 shares in the last quarter. BlackRock Fund Advisors raised its position in shares of Charles River Laboratories International by 5.1% in the second quarter. BlackRock Fund Advisors now owns 1,754,797 shares of the company’s stock valued at $144,665,000 after buying an additional 85,280 shares in the last quarter. BlackRock Institutional Trust Company N.A. raised its position in shares of Charles River Laboratories International by 11.3% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 1,560,358 shares of the company’s stock valued at $128,636,000 after buying an additional 157,909 shares in the last quarter. Finally, State Street Corp raised its position in shares of Charles River Laboratories International by 0.6% in the second quarter. State Street Corp now owns 1,297,848 shares of the company’s stock valued at $106,990,000 after buying an additional 8,266 shares in the last quarter. 97.17% of the stock is currently owned by institutional investors and hedge funds.

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Charles River Laboratories International Inc. (NYSE:CRL) traded down 0.13% during mid-day trading on Tuesday, reaching $71.47. 234,634 shares of the company were exchanged. The company has a market capitalization of $3.38 billion, a PE ratio of 24.15 and a beta of 1.18. Charles River Laboratories International Inc. has a one year low of $65.70 and a one year high of $89.18. The stock has a 50-day moving average price of $76.01 and a 200 day moving average price of $81.84.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Wednesday, November 2nd. The company reported $1.18 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.13 by $0.05. The business had revenue of $425.70 million for the quarter, compared to the consensus estimate of $291.20 million. Charles River Laboratories International had a net margin of 9.05% and a return on equity of 25.31%. The company’s quarterly revenue was up 21.8% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.03 EPS. Analysts predict that Charles River Laboratories International Inc. will post $4.47 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Charles River Laboratories International Inc. (CRL) Shares Bought by Olstein Capital Management L.P.” was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another website, it was copied illegally and reposted in violation of United States & international copyright & trademark laws. The original version of this story can be read at https://www.thecerbatgem.com/2016/11/29/charles-river-laboratories-international-inc-crl-shares-bought-by-olstein-capital-management-l-p.html.

CRL has been the topic of several research analyst reports. Bank of America Corp. set a $93.00 target price on shares of Charles River Laboratories International and gave the stock a “buy” rating in a research note on Friday, November 18th. Zacks Investment Research raised shares of Charles River Laboratories International from a “hold” rating to a “buy” rating and set a $75.00 price objective on the stock in a research note on Thursday, November 3rd. Jefferies Group raised their price objective on shares of Charles River Laboratories International from $94.00 to $100.00 and gave the company a “buy” rating in a research note on Thursday, August 4th. Citigroup Inc. raised their price objective on shares of Charles River Laboratories International from $85.00 to $90.00 and gave the company a “neutral” rating in a research note on Thursday, August 4th. Finally, Evercore ISI reaffirmed a “hold” rating and issued a $91.50 price objective (up from $83.50) on shares of Charles River Laboratories International in a research note on Thursday, August 4th. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating and five have given a buy rating to the company’s stock. Charles River Laboratories International has an average rating of “Hold” and an average price target of $84.96.

In other news, Director C Richard Reese sold 4,539 shares of the company’s stock in a transaction dated Monday, November 28th. The shares were sold at an average price of $71.93, for a total value of $326,490.27. Following the sale, the director now directly owns 44,943 shares of the company’s stock, valued at approximately $3,232,749.99. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 2.30% of the stock is currently owned by insiders.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a full service, early-stage contract research company. The Company is engaged in the business of providing the research models required in research and development of new drugs, devices and therapies. The Company operates through three segments: Research Models and Services (RMS), which consists of Research Models and Research Model Services; Discovery and Safety Assessment (DSA), which offers discovery and safety assessment services, both regulated and non-regulated, in which it includes both in vivo and in vitro studies, and Manufacturing Support (Manufacturing), which includes Microbial Solutions, Biologics Testing Solutions and Avian Vaccine Services.

5 Day Chart for NYSE:CRL

Receive News & Stock Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related stocks with our FREE daily email newsletter.